Could TB treatment be cut from 6 months to 17 weeks?

NCT ID NCT05766267

Ongoing Disease control Sponsor: Centers for Disease Control and Prevention Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether two new 17-week drug combinations can treat pulmonary tuberculosis as effectively as the standard 6-month regimen. About 288 people with TB will receive one of three daily pill regimens. The goal is to see if shorter treatment can clear the infection faster and with fewer side effects, potentially making it easier for patients to stick with therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Combination of bedaquiline, moxifloxacin, pyrazinamide, plus either rifabutin or delamanid
What this could lead to: If successful, this could lead to a shorter, 17-week treatment for tuberculosis, making it easier for patients to complete therapy and reduce the spread of the disease.
What could go wrong: This is a mid-stage trial with only 288 participants, so results may not apply to everyone. The shorter regimens might be less effective or cause more side effects than the standard 6-month treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection pulmonary tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS INFECTION TUBERCULOSIS, PULMONARY

Contacts and locations

Locations

McGill University Health Centre

Montreal, Canada
TBTC Site 09 University of Cape Town Lung Institute (Pty) Ltd

Mowbray, Cape Town, 7700, South Africa
TBTC Site 26 Seattle & King County TB Control Program

Seattle, Washington, 98104, United States
TBTC Site 30 Uganda-Case Western Reserve Research Collaboration

Kampala, Uganda
TBTC Site 45 Les Centres Gheskio (INLR)

Port-au-Prince, Ouest, HT6110, Haiti
TBTC Site 67 GHESKIO centers IMIS

Port-au-Prince, Ouest, HT 6124, Haiti
TBTC Site 76 CAB-V. Can Tho Province, Vietnam - Thot Not District TB Unit

Can Tho, Can Tho City, 70000, Vietnam
Vancouver, British Columbia Centre for Disease Control

Vancouver, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.